Upgrades Neutral Overweight X

MYGN Myriad Genetics

Piper Sandler

$11.50 $12.50

Initiated Buy X

MYGN Myriad Genetics

Craig Hallum

$29

Initiated Neutral X

MYGN Myriad Genetics

UBS

$18

Downgrades Outperform Mkt Perform X

MYGN Myriad Genetics

Leerink Partners

$30 $21

Initiated Equal-Weight X

MYGN Myriad Genetics

Morgan Stanley

$32

Initiated Overweight X

MYGN Myriad Genetics

Wells Fargo

$35

Initiated Sector Outperform X

MYGN Myriad Genetics

Scotiabank

$29

Resumed Underperform X

MYGN Myriad Genetics

Jefferies

$20

Upgrades Mkt Perform Outperform X

MYGN Myriad Genetics

Leerink Partners

$25 $35

Resumed Neutral X

MYGN Myriad Genetics

Piper Sandler

$23

Initiated Equal Weight X

MYGN Myriad Genetics

Wells Fargo

$20

Initiated Buy X

MYGN Myriad Genetics

Guggenheim

$23

Initiated Outperform X

MYGN Myriad Genetics

Wolfe Research

$28

Resumed Underweight X

MYGN Myriad Genetics

JP Morgan

$18

Upgrades Sell Buy X

MYGN Myriad Genetics

Goldman

$18 $25

Upgrades Mkt Perform Outperform X

MYGN Myriad Genetics

Raymond James

$25

Initiated Equal-Weight X

MYGN Myriad Genetics

Stephens

$22

Resumed Market Perform X

MYGN Myriad Genetics

Cowen

$33

Initiated Mkt Perform X

MYGN Myriad Genetics

Raymond James

Initiated Sell X

MYGN Myriad Genetics

Goldman

$25

Downgrades Overweight Neutral X

MYGN Myriad Genetics

Piper Jaffray

$45 $40

Upgrades Underperform Neutral X

MYGN Myriad Genetics

BofA/Merrill

Upgrades Underweight Eq Weight X

MYGN Myriad Genetics

Barclays

$18 $40

Downgrades Strong Buy Hold X

MYGN Myriad Genetics

Needham

Downgrades Outperform Mkt Perform X

MYGN Myriad Genetics

Cowen

Reiterated Strong Buy X

MYGN Myriad Genetics

Needham

$37 $41

Initiated Strong Buy X

MYGN Myriad Genetics

Needham

$36

Upgrades Sell Neutral X

MYGN Myriad Genetics

Goldman

Upgrades Neutral Overweight X

MYGN Myriad Genetics

Piper Jaffray

Upgrades Eq-Weight Overweight X

MYGN Myriad Genetics

Morgan Stanley

Upgrades Underweight Eq-Weight X

MYGN Myriad Genetics

Morgan Stanley

Initiated Sell X

MYGN Myriad Genetics

Goldman

$32

MYGN  Myriad Genetics, Inc.

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.